Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: liver, addiction
- Who it enrolls
- age 18 Years to 65 Years; BMI ≥85 required; conditions: Metformin; Obesity, Abdominal; Diabetes Mellitus, Type 2; Abdominal Fat
- Interventions
- Liraglutide; Semaglutide; Metformin
- Conditions
- Metformin; Obesity, Abdominal; Diabetes Mellitus, Type 2; Abdominal Fat; Non-Alcoholic Fatty Liver Disease; Metabolism Disorder, Glucose; Metabolism Disorder, Lipid
- Phase and size
- NA · 300 participants
- Dates
- Start 2023-02-23
Primary completion 2025-02-23 - Sponsor
- RenJi Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Blood glucoseThe twelfth week of treatment
- Blood insulinThe twelfth week of treatment
- Total cholesterolThe twelfth week of treatment
- TriglycerideThe twelfth week of treatment
- LipoproteinThe twelfth week of treatment
- WeightThe twelfth week of treatment
- Abdominal fat distributionThe twelfth week of treatment
02Eligibility
Who can take part
Inclusion Criteria: * Aged 18-65 years old * BMI≥24kg/㎡, or waist circumference: \> 85cm (for male) or \> 80cm (for female) * Has been diagnosed with type 2 diabetes mellitus * Good blood glucose control in recent three months: random blood sugar \< 14mmol/L and HbA1c 6-9% * Not received any drugs affecting glucose and lipid metabolism or weight loss surgery in the past one month Exclusion Criteria: * Abnormal weight gain caused by other endocrine diseases * Severe metabolic diseases, such as diabetic ketoacidosis, hypertonic hyperglycemia * Type 1 diabetes or other special types of diabetes * Used drugs affecting glycolipid metabolism in the past three months * Severe bleeding tendency that unable to complete venous blood collection * Patients with MRI contraindications * Severe renal insufficiency or severe liver insufficiency * Patients with advanced malignant tumors * Serious cardiovascular and cerebrovascular diseases * Rheumatic and immune diseases * Pregnant and lactating women
03Change log
Registry changes
No changes recorded since the trial was added.